{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:36:34Z","timestamp":1788903394256,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009448","name":"Universit\u00e0 degli Studi della Campania Luigi Vanvitelli","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009448","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Approximately 30% of patients present alterations in the FMS-like receptor tyrosine kinase 3 (FLT3) gene, which are associated with poor prognosis. FLT3 inhibitors \u2013 midostaurin (first-generation), gilteritinib and quizartinib (second-generation) \u2013 have been developed to block FLT3 activation. Given the need of optimizing treatment in FLT3-mutated AML, we conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to compare the safety profiles of FLT3 inhibitors. Following the PRISMA statement, we searched Embase, MEDLINE and Cochrane Library. The Cochrane Risk of Bias Tool for RCTs was used for quality assessment. Of 2132 references, seven RCTs, involving 2409 adult patients, met inclusion criteria: quizartinib and midostaurin in two trials each and gilteritinib in three. The most frequently reported adverse events (AEs) were classified under the System Organ Class (SOC) Blood and lymphatic system disorders (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u20095474, 58.4% of them related to FLT3 inhibitors). The most frequently observed non-hematological AEs were gastrointestinal disorders, pyrexia, elevated ALT\/AST and headache. FLT3 inhibitors are not associated with a significant increase in the risk of AEs compared to standard treatments. No meaningful differences in AE risk were observed among the three drugs. The only exception was an higher risk of ALT increased with gilteritinib (RR\u2009=\u20092.40, 95% CI: 1.16\u20134.95). Future studies should stratify safety outcomes by demographic and clinical characteristics and incorporate long-term follow-up for a more comprehensive safety assessment in clinical practice.\n                  <\/jats:p>","DOI":"10.1007\/s10238-026-02093-8","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:01:43Z","timestamp":1771840903000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety profile of FLT3 inhibitors in acute myeloid leukemia: a systematic review and meta-analysis of adverse events"],"prefix":"10.1007","volume":"26","author":[{"given":"Mario","family":"Gaio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Cagnotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Frasca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica Vittoria","family":"Laino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2093_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6:e441. https:\/\/doi.org\/10.1038\/bcj.2016.50.","journal-title":"Blood Cancer J"},{"key":"2093_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005.","journal-title":"Blood Rev"},{"key":"2093_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/asheducation-2012.1.1","volume":"2012","author":"A.K Burnett","year":"2012","unstructured":"Burnett A.K. Treatment of acute myeloid leukemia: are we making progress? Hematol Am Soc Hematol Educ Program. 2012;2012:1\u20136. https:\/\/doi.org\/10.1182\/asheducation-2012.1.1.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2093_CR4","doi-asserted-by":"publisher","unstructured":"Alsulami HA, Alnashri MM, Bawazir AF, Alrashid LT, Dly RA, Alharbi YA, Qari MH. Prognostics and Clinical Outcomes in Patients Diagnosed With Acute Myeloid Leukemia (AML) in a Teaching Hospital. Cureus 13, e18915. https:\/\/doi.org\/10.7759\/cureus.18915","DOI":"10.7759\/cureus.18915"},{"key":"2093_CR5","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3.","journal-title":"Lancet"},{"key":"2093_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2093_CR7","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/cas.14274","volume":"111","author":"H Kiyoi","year":"2020","unstructured":"Kiyoi H, Kawashima N, Ishikawa Y. FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development. Cancer Sci. 2020;111:312\u201322. https:\/\/doi.org\/10.1111\/cas.14274.","journal-title":"Cancer Sci"},{"key":"2093_CR8","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650\u201365. https:\/\/doi.org\/10.1038\/nrc1169.","journal-title":"Nat Rev Cancer"},{"key":"2093_CR9","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","volume":"100","author":"PD Kottaridis","year":"2002","unstructured":"Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood. 2002;100:2393\u20138. https:\/\/doi.org\/10.1182\/blood-2002-02-0420.","journal-title":"Blood"},{"key":"2093_CR10","doi-asserted-by":"publisher","unstructured":"Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.612880.","DOI":"10.3389\/fonc.2020.612880"},{"key":"2093_CR11","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532\u201342. https:\/\/doi.org\/10.1182\/blood-2002-02-0492.","journal-title":"Blood"},{"key":"2093_CR12","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2006-04-015826","volume":"110","author":"AJ Mead","year":"2007","unstructured":"Mead AJ, Linch DC, Hills RK, Wheatley K, Burnett AK, Gale RE. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood. 2007;110:1262\u201370. https:\/\/doi.org\/10.1182\/blood-2006-04-015826.","journal-title":"Blood"},{"key":"2093_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312. https:\/\/doi.org\/10.1038\/s41375-018-0357-9.","journal-title":"Leukemia"},{"key":"2093_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2093_CR15","unstructured":"Julian PT, March Higgins Chap. 8: Assessing Risk of Bias in a Randomized Trial Available online: https:\/\/training.cochrane.org\/handbook\/current\/chapter-08 (accessed on 18 2025)."},{"key":"2093_CR16","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","volume":"20","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20:984\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(19)30150-0.","journal-title":"Lancet Oncol"},{"key":"2093_CR17","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383. https:\/\/doi.org\/10.1016\/S0140-6736(23)00464-6.","journal-title":"Lancet"},{"key":"2093_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56:1180\u20139. https:\/\/doi.org\/10.1038\/s41409-020-01153-1.","journal-title":"Bone Marrow Transplant"},{"key":"2093_CR19","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1902688.","journal-title":"N Engl J Med"},{"key":"2093_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364. https:\/\/doi.org\/10.1056\/NEJMoa1614359.","journal-title":"N Engl J Med"},{"key":"2093_CR21","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang ES, Montesinos P, Minden MD, Lee J-H, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut\u2009+\u2009AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"key":"2093_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02382-9","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang B, Li J, Liu L, Du X, Jiang H, et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 2024. https:\/\/doi.org\/10.1038\/s41375-024-02382-9.","journal-title":"Leukemia"},{"key":"2093_CR23","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"E Wang","year":"2022","unstructured":"Wang E, Montesinos P, Minden M, Lee J, Heuser M, Naoe T, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut\u2009+\u2009AML ineligible for intensive chemotherapy. Blood. 2022;140:1845\u201357. https:\/\/doi.org\/10.1182\/blood.2021014586.","journal-title":"Blood"},{"key":"2093_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","volume":"34","author":"AI Antar","year":"2020","unstructured":"Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020;34:682\u201396. https:\/\/doi.org\/10.1038\/s41375-019-0694-3.","journal-title":"Leukemia"},{"key":"2093_CR25","first-page":"19","volume":"88","author":"I Moreno","year":"2003","unstructured":"Moreno I, Mart\u00edn G, Bolufer P, Barrag\u00e1n E, Rueda E, Rom\u00e1n J, Fern\u00e1ndez P, Le\u00f3n P, Mena A, Cervera J, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88:19\u201324.","journal-title":"Haematologica"},{"key":"2093_CR26","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2007-08-107946","volume":"111","author":"SP Whitman","year":"2008","unstructured":"Whitman SP, Ruppert AS, Radmacher MD, Mr\u00f3zek K, Paschka P, Langer C, et al. FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008;111:1552\u20139. https:\/\/doi.org\/10.1182\/blood-2007-08-107946.","journal-title":"Blood"},{"key":"2093_CR27","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","volume":"111","author":"U Bacher","year":"2008","unstructured":"Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters\u2013an analysis of 3082 patients. Blood. 2008;111:2527\u201337. https:\/\/doi.org\/10.1182\/blood-2007-05-091215.","journal-title":"Blood"},{"key":"2093_CR28","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00277-014-2072-6","volume":"93","author":"M Port","year":"2014","unstructured":"Port M, B\u00f6ttcher M, Thol F, Ganser A, Schlenk R, Wasem J, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis. Ann Hematol. 2014;93:1279\u201386. https:\/\/doi.org\/10.1007\/s00277-014-2072-6.","journal-title":"Ann Hematol"},{"key":"2093_CR29","doi-asserted-by":"publisher","unstructured":"Kamphuis P, van Zeventer IA, de Graaf AO, Salzbrunn JB, van Bergen MGJM, Dinmohamed AG, van der Reijden BA, Schuringa JJ, Jansen JH, Huls G. Sex differences in the spectrum of clonal hematopoiesis. HemaSphere. 2023;7(e832). https:\/\/doi.org\/10.1097\/HS9.0000000000000832.","DOI":"10.1097\/HS9.0000000000000832"},{"key":"2093_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119091","volume":"269","author":"RS Kumar","year":"2021","unstructured":"Kumar RS, Goyal N. Estrogens as regulator of hematopoietic stem cell, immune cells and bone biology. Life Sci. 2021;269:119091. https:\/\/doi.org\/10.1016\/j.lfs.2021.119091.","journal-title":"Life Sci"},{"key":"2093_CR31","doi-asserted-by":"publisher","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM Survival of Adult AML Patients Treated with Chemotherapy in the U.S. Population by Age, Race and Ethnicity, Sex, Calendar-Year Period, and, Subgroup AML. 2001\u20132019. EClinicalMedicine 2024, 71, 102549. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102549","DOI":"10.1016\/j.eclinm.2024.102549"},{"key":"2093_CR32","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/bjh.17523","volume":"194","author":"PH Wiernik","year":"2021","unstructured":"Wiernik PH, Sun Z, Cripe LD, Rowe JM, Fernandez HF, Luger SM, Lazarus HM, Paietta EM, Tallman MS, Litzow MR. Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia. Br J Haematol. 2021;194:309\u201318. https:\/\/doi.org\/10.1111\/bjh.17523.","journal-title":"Br J Haematol"},{"key":"2093_CR33","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2117344.","journal-title":"N Engl J Med"},{"key":"2093_CR34","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/s41375-024-02435-z","volume":"38","author":"JM Tettero","year":"2024","unstructured":"Tettero JM, Cloos J, Bullinger L. Acute myeloid leukemia: does sex matter? Leukemia. 2024;38:2329\u201331. https:\/\/doi.org\/10.1038\/s41375-024-02435-z.","journal-title":"Leukemia"},{"key":"2093_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00911-w","volume":"13","author":"NJ Short","year":"2023","unstructured":"Short NJ, Nguyen D, Ravandi F. Treatment of older adults with FLT3-mutated AML: emerging paradigms and the role of frontline FLT3 inhibitors. Blood Cancer J. 2023;13:142. https:\/\/doi.org\/10.1038\/s41408-023-00911-w.","journal-title":"Blood Cancer J"},{"key":"2093_CR36","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1182\/blood-2010-04-261867","volume":"116","author":"T Kindler","year":"2010","unstructured":"Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116:5089\u2013102. https:\/\/doi.org\/10.1182\/blood-2010-04-261867.","journal-title":"Blood"},{"key":"2093_CR37","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/onc.2010.273","volume":"29","author":"E Weisberg","year":"2010","unstructured":"Weisberg E, Sattler M, Ray A, Griffin JD. Drug resistance in mutant FLT3-positive AML. Oncogene. 2010;29:5120\u201334. https:\/\/doi.org\/10.1038\/onc.2010.273.","journal-title":"Oncogene"},{"key":"2093_CR38","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117:3286\u201393. https:\/\/doi.org\/10.1182\/blood-2010-01-266742.","journal-title":"Blood"},{"key":"2093_CR39","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1188\/06.ONF.1193-1201","volume":"33","author":"A Nirenberg","year":"2006","unstructured":"Nirenberg A, Bush AP, Davis A, Friese CR, Gillespie TW, Rice RD. Neutropenia: State of the Knowledge Part I. Oncol Nurs Forum. 2006;33:1193\u2013201. https:\/\/doi.org\/10.1188\/06.ONF.1193-1201.","journal-title":"Oncol Nurs Forum"},{"key":"2093_CR40","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.2147\/CMAR.S166387","volume":"10","author":"M Yang","year":"2018","unstructured":"Yang M, Zhao J, Liu T, Yang X, Wei H, Xu W, et al. Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis. Cancer Manag Res. 2018;10:2635\u201352. https:\/\/doi.org\/10.2147\/CMAR.S166387.","journal-title":"Cancer Manag Res"},{"key":"2093_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-020-01540-1","volume":"9","author":"S Majothi","year":"2020","unstructured":"Majothi S, Adams D, Loke J, Stevens SP, Wheatley K, Wilson JS. FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis. Syst Rev. 2020;9:285. https:\/\/doi.org\/10.1186\/s13643-020-01540-1.","journal-title":"Syst Rev"},{"key":"2093_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116869","volume":"236","author":"Y Yin","year":"2025","unstructured":"Yin Y, Cao Y, Zhou Y, Xu Z, Luo P, Yang B, et al. Downregulation of DDIT4 levels with borneol attenuates hepatotoxicity induced by gilteritinib. Biochem Pharmacol. 2025;236:116869. https:\/\/doi.org\/10.1016\/j.bcp.2025.116869.","journal-title":"Biochem Pharmacol"},{"key":"2093_CR43","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00432-022-03995-2","volume":"149","author":"R Tober","year":"2023","unstructured":"Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J, Glaser A, Thiede C, Hochhaus A, Scholl S. Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia. J Cancer Res Clin Oncol. 2023;149:1569\u201383. https:\/\/doi.org\/10.1007\/s00432-022-03995-2.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2093_CR44","unstructured":"Clinical Practice Guidelines on Infectious Complications of Targeted Drugs and Biotherapies. European Conference on Infections in Leukaemia (ECIL) Available online: https:\/\/aml-hub.com\/medical-information\/clinical-practice-guidelines-on-infectious-complications-of-targeted-drugs-and-biotherapies-european-conference-on-infections-in-leukaemia-ecil (accessed on 3 July 2025)."}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02093-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02093-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:06:36Z","timestamp":1772546796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02093-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02093-8","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"167"}}